[{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Not Applicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Equillium","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Equillium","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Immunology","graph2":"Phase I","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"6","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SOUTH AFRICA","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Rh-insulin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Insulin aspart","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Not Applicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Bicara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"BCA101","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biocon","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"7","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","graph1":"Oncology","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Viatris"},{"orgOrder":0,"company":"Biocon","sponsor":"Equillium","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Invivyd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"ADG20","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"9","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Equillium","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"6","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biocon \/ Not Applicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SAUDI ARABIA","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pen Injection","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Equillium","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon \/ Equillium","highestDevelopmentStatusID":"6","companyTruncated":"Biocon \/ Equillium"},{"orgOrder":0,"company":"Biocon","sponsor":"Equillium","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Insulin Lispro","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Yoshindo","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12","graph1":"Dermatology","graph2":"Phase III","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Liraglutide","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biocon \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Biocon \/ Zentiva"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biocon \/ Not Applicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Biocon","amount2":3.3399999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":3.3399999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Insulin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biocon \/ Not Applicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Insulin Glargine","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Biocon","amount2":3.3399999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":3.3399999999999999,"dosageForm":"Injection","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab-maly","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-fkjp","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Not Applicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biocon \/ Not Applicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Juno Pharmaceuticals Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Liraglutide","moa":"","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Juno Pharmaceuticals Pty Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Juno Pharmaceuticals Pty Ltd"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Eris Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Everolimus","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Biocon Biologics \/ Eris Lifesciences","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Eris Lifesciences"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocon Biologics \/ Sandoz B2B","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Sandoz B2B"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Eris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Metoprolol Succinate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Biocon Biologics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.14999999999999999,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Biocon Biologics \/ Eris Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Eris Pharmaceuticals"},{"orgOrder":0,"company":"Biocon","sponsor":"Zentiva","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Zentiva"},{"orgOrder":0,"company":"Biocon","sponsor":"Biomm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2024","type":"Partnership","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Biomm","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Biomm"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Not Applicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Medix","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"MEXICO","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Liraglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Biocon Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Biocon Biologics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Biocon","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SAUDI ARABIA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"GLP-1-based Drug","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Biocon \/ Biocon","highestDevelopmentStatusID":"1","companyTruncated":"Biocon \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Not Applicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Biocon Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Inapplicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12\/23","graph1":"Dermatology","graph2":"Phase III","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biocon Biologics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Biocon

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : Yesintek (ustekinumab), is an approved IL-12/IL-23 inhibitor is given once in 12 weeks SC and IV for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.

                          Product Name : Yesintek

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 07, 2025

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : gVictoza (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.

                          Product Name : Liraglutide Biocon

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          February 27, 2025

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : Yesintek (ustekinumab), is an approved IL-12/IL-23 inhibitor is given once in 12 weeks SC and IV for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.

                          Product Name : Yesintek

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 24, 2025

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : Yesintek (ustekinumab), is an approved IL-12/IL-23 inhibitor is given once in 12 weeks SC and IV for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.

                          Product Name : Yesintek

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 21, 2025

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : Yesintek (ustekinumab), is an approved IL-12/IL-23 inhibitor is given once in 12 weeks SC and IV for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.

                          Product Name : Yesintek

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          January 07, 2025

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : Yesintek (ustekinumab), is an approved IL-12/IL-23 inhibitor is given once in 12 weeks SC and IV for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.

                          Product Name : Yesintek

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 02, 2024

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : The agreement will focus on commercialising GLP-1 products for diabetes and chronic weight management in select countries of the Middle East.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 27, 2024

                          Lead Product(s) : GLP-1-based Drug

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Recipient : Tabuk Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : Sacubitril and valsartan is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.

                          Product Name : Entresto-Generic

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 02, 2024

                          Lead Product(s) : Sacubitril Sodium,Valsartan

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : The agreement aims to commercialize its Bmab 1200, a proposed biosimilar to Stelara and a monoclonal antibody medication, in Europe, the United Kingdom (UK), Canada, and Japan.

                          Product Name : Bmab 1200

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 29, 2024

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Johnson & Johnson Innovative Medicine

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          10

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : Yesafili (aflibercept) is a PGF & VEGF-A inhibitor, its single-dose vial formulation is approved for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema.

                          Product Name : Yesafili

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 21, 2024

                          Lead Product(s) : Aflibercept

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank